OccuRx
OccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.
Backed by
Medical Research Commercialisation Fund
Uniseed
Brandon CapitalRaised 5.15M EQUITY on May 19, 2015
About
OccuRx is a Melbourne-based biopharmaceutical company developing a novel class of anti-fibrotic therapeutics, with a lead compound showing preclinical efficacy in animal models of ocular inflammation and fibrosis.
Mission
OccuRx is a Melbourne, Victoria, Australia-based biopharmaceutical company launched to develop a new class of drugs to prevent the health burden associated with fibrosis. Led by Dr Darren Kelly, the company has established preclinical proof of concept with its lead anti-fibrotic compound in an animal model of ocular inflammation and fibrosis. OccuRx intends to use the funds to continue development of its compound. The company launched with up to AU$6.5M available in staged tranches of venture capital funding. Investment came from a consortium including the Medical Research Commercialisation Fund (MRCF), Brandon Capital Partners and Uniseed.
Quick Facts
Founded
2014
Funding
EQUITY
Industry
Biopharma, Biotechnology, Medical, Therapeutics
Team Size
1-10
Headquarters
Melbourne, Victoria, Australia
Careers
View Careers Page
No open roles at this time.
Check their careers page for updates